nukes
no way to compare when less than two revisions
Differences
This shows you the differences between two versions of the page.
Next revision | |||
— | nukes [2017/07/07 18:30] – external edit 127.0.0.1 | ||
---|---|---|---|
Line 1: | Line 1: | ||
+ | ====== Infection/ | ||
+ | ===== In 111 WBC ===== | ||
+ | * active inflam/infx | ||
+ | * spleen> | ||
+ | * 1 hr IBD | ||
+ | * 4 hr abdomen | ||
+ | * 24 hr whole body | ||
+ | ===== In 111 WBC w/ SC ===== | ||
+ | * since In-WBC can be hot with marrow activation, get SC scan | ||
+ | * if In-WBC is hot and SC cold, then likely infected | ||
+ | * if both hot, then just bone marrow activation | ||
+ | |||
+ | ===== Ga 67 ===== | ||
+ | * iron analogue | ||
+ | * goes where iron goes - salivary and lacrymal glands, liver, bowel | ||
+ | * can see cardiac activity for the first few hours | ||
+ | * if cardiac activity persists, ddx myocarditis, | ||
+ | * used for inflammation, | ||
+ | * should not see renal act after 24h | ||
+ | * pulmonary gallium score - used to evaluate sarcoid response to therapy | ||
+ | |||
+ | ===== Tc MDP ===== | ||
+ | * 140 kev | ||
+ | * flow 60s | ||
+ | * pool 5m | ||
+ | * delay 2-3h | ||
+ | * kidneys, liver, breast, lung, extremities | ||
+ | * ddx increased liver uptake - mets from mucinous adenoCA, amyloid, acute hepatic necrosis, impurities | ||
+ | |||
+ | ====== Thyroid/ | ||
+ | |||
+ | ===== General ===== | ||
+ | * Palpate gland and ask for RAIU for every scan | ||
+ | * RAIU can be determined using either I-131 (7 µCi) or I-123 (200-300 µCi) | ||
+ | * Nl 4hr RAIU = 5-15% | ||
+ | * Nl 24hr RAIU = 10-30% | ||
+ | |||
+ | ===== Therapy ===== | ||
+ | |||
+ | ==== Contraindications to I-131 therapy ==== | ||
+ | * Pregnancy: Radioiodine freely crosses the placenta. Additionally, | ||
+ | * Breast feeding: Both iodine and pertechnetate are excreted in breast milk | ||
+ | * Severe thyrotoxicity: | ||
+ | |||
+ | ==== Drug interactions ==== | ||
+ | ^ Medication | ||
+ | | Antithyroid medication (propylthiouracil, | ||
+ | | Thyroid hormone | 2 weeks for cytomel\\ 4 to 6 weeks for synthyroid | | ||
+ | | Kelp, Lugol' | ||
+ | | IV contrast | Over 1 month | | ||
+ | | Amiodarone | 3 to 6 months | | ||
+ | |||
+ | ==== Alternatives ==== | ||
+ | * PTU, surgery, do nothing | ||
+ | |||
+ | ==== Dose calculations ==== | ||
+ | * complicated - (rads * wt of gland) / (900 * RAIU) | ||
+ | * simplified - (0.12mCi * wt of gland (in grams)) / % uptake | ||
+ | * easiest - empirically treat 12mCi for Graves and 29.9mCi for multinodular goiter | ||
+ | |||
+ | |||
+ | ===== Thyroid Patterns ===== | ||
+ | * graves - increased RAIU | ||
+ | * acute - no uptake or patchy faint uptake | ||
+ | * subacute - decreased uptake | ||
+ | * hashimoto' | ||
+ | |||
+ | ==== Congenital ==== | ||
+ | * Thyroid dysgenesis (anatomic abnormalities) - aplasia, hypoplasia, or ectopy of the thyroid gland, often with hypoplasia | ||
+ | * insufficient tissue to match the demands | ||
+ | * abnormal anatomy is seen on thyroid scanning | ||
+ | * Dyshormonogenesis (organification defects) - serious error in thyroid hormone synthesis | ||
+ | * thyroid trapping of pertechnetate or iodine will be increased | ||
+ | * Hypopituitarism (secondary hypothyroidism) - pituitary aplasia or midline brain developmental defects | ||
+ | * may also be hypothalamic dysfunction (tertiary hypothyroidism) | ||
+ | * anatomically normal thyroid will show reduced uptake | ||
+ | * Pendred syndrome | ||
+ | * sensorineural hearing loss | ||
+ | * goiter, usually not present until puberty at which time the thyroid becomes diffusely enlarged | ||
+ | * affected individuals generally remain euthyroid despite the goiter | ||
+ | * thyroid defect is associated with abnormal iodide processing, that often can be diagnosed using the perchlorate discharge test | ||
+ | * potassium perchlorate - competitive inhibitor of iodide transport into the thyroid | ||
+ | |||
+ | ===== I 123 ===== | ||
+ | * dose -> 200-400 µCi orally | ||
+ | * 4h image, 24 RAIU | ||
+ | * thyroid, gastric, renal/ | ||
+ | * better resolution than < | ||
+ | * not used much b/c of cost | ||
+ | |||
+ | ===== I 131 ===== | ||
+ | * 369 keV | ||
+ | * uptake in thyroid, kidneys, stomach, colon, and salivary glands | ||
+ | * liver activity if functioning thyroid tissue present | ||
+ | * Doses: | ||
+ | * 30-50 µCi thyroid scan | ||
+ | * 2-5 mCi cancer f/u | ||
+ | * 20-30 mCi therapy for toxic multinodular goiter | ||
+ | * 100-200 mCi for thyroid carcinoma | ||
+ | * imaging done @ 48-72 hr to reduce background | ||
+ | * liver uptake means funct thyroid tissue or tumor present | ||
+ | * contraindicated during pregnancy (crosses placenta) | ||
+ | |||
+ | ==== Short-term complications ==== | ||
+ | * sialadenitis | ||
+ | * gastritis | ||
+ | * azoospermia | ||
+ | * thyroid storm | ||
+ | |||
+ | ==== Long-term complications ==== | ||
+ | * pulmonary fibrosis | ||
+ | * bone marrow depression | ||
+ | * lymphoma/ | ||
+ | * hypothyroidism | ||
+ | |||
+ | ===== Pertechnetate ===== | ||
+ | * trapped by the thyroid gland in the same manner as iodine (an active transport mechanism) | ||
+ | * after trapping pertechnetate slowly " | ||
+ | * typical dose is 3 mCi IV | ||
+ | * do NOT need to stop PTU | ||
+ | * PTU blocks oxidation and organification of iodide following its uptake by the thyroid gland, but will not interfere with trapping of pertechnetate | ||
+ | |||
+ | ===== Tc sestamibi ===== | ||
+ | * mitochondrial uptake | ||
+ | * early = 10-20 min, thyroid & parathyroid visible | ||
+ | * late = 2-3 hours, thyroid washes out\\ | ||
+ | Causes of increased activity on delayed images: | ||
+ | * parathyroid adenoma - focal uptake w/ history of hypercalcemia | ||
+ | * thyroid cancer / thyroid adenoma - less likely possibilities | ||
+ | * parathyroid hyperplasia - multiple foci of increased uptake | ||
+ | |||
+ | ====== Liver ====== | ||
+ | |||
+ | |||
+ | ===== IDA ===== | ||
+ | * cardiac bp clears in < 5m | ||
+ | * uniform liver activity at 15 min | ||
+ | * gallbladder seen < 30m | ||
+ | * sm bowel < 1h | ||
+ | * no GB @ 4h dx acute chole | ||
+ | * 2mg morphine (do not give until you see bowel) or 24h delay | ||
+ | * 0.04 mg/kg per Evan protocol | ||
+ | * ideal prep is npo for 4-12 hrs | ||
+ | * if npo for greater than 24 hrs, the GB will be full | ||
+ | * don't scan preemies right away (false positives) | ||
+ | |||
+ | |||
+ | ==== Gallbladder Ejection Fraction ==== | ||
+ | * Normal: ≥50% | ||
+ | * Borderline: 35-49% | ||
+ | * Decreased: <35% | ||
+ | |||
+ | ==== Delayed Biliary to Bowel Transit ==== | ||
+ | * Nonspecific finding which can be secondary to: | ||
+ | * Chronic cholecystitis | ||
+ | * Partial common bile duct obstruction | ||
+ | * Can be a normal variant in up to 20% of patients | ||
+ | |||
+ | ===== Tc SC ===== | ||
+ | * Ratio of Liver: | ||
+ | * Colloid shift = portal HTN | ||
+ | * FNH is basically the only liver mass to take up SC (Kupffer cells) | ||
+ | |||
+ | |||
+ | |||
+ | ====== Gastric Emptying ====== | ||
+ | * Normal solid phase emptying: 50% by 90-120 minutes. | ||
+ | * Normal liquid phase emptying: 50% by 60 minutes. | ||
+ | |||
+ | ====== Oncology ====== | ||
+ | |||
+ | ===== PET ===== | ||
+ | * Prep | ||
+ | * NPO after midnight | ||
+ | * no physical activity | ||
+ | * cold, dark room with no stimulation | ||
+ | * feed the heart, starve cancer - means give glucose + insulin prior to cardiac PET; fasting for cancer studies | ||
+ | * flare effect - SUVs will temporarily (first several weeks) rise after Tamoxifen therapy for breast CA in responders. | ||
+ | |||
+ | ===== I 131 MIBG ===== | ||
+ | * pheo, neuroblastoma, | ||
+ | * drugs block MIBG -> cocaine, TCA, thorazine, CCB, B-blockers | ||
+ | * must protect thyroid w/ supersat iodine (Lugol' | ||
+ | |||
+ | ===== In 111 octreoscan (pentreotide) ===== | ||
+ | * spleen, kidneys, bladder, liver | ||
+ | * neuroendocrine tumor, glioma, pit ad, breast, granulomatous dz, MTC | ||
+ | ===== In 111 Prostascint ===== | ||
+ | * look for L supraclavicular node = Virchow node | ||
+ | |||
+ | ====== Neuro ====== | ||
+ | |||
+ | ===== Brain perfusion study or FDG-PET ===== | ||
+ | * Indications | ||
+ | * Dementia | ||
+ | * Alzheimers - decreased parietotemporal activity | ||
+ | * Pick's - decreased frontal activity | ||
+ | * Multi-infarct dementia - multiple defects, vascular territories, | ||
+ | * Dementia with Lewy bodies - diffuse glucose hypometabolism, | ||
+ | * Seizure focus | ||
+ | * usually done interictal - decreased activity in area of seizure focus | ||
+ | * Residual tumor vs. radiation | ||
+ | * residual tumor will have uptake, radiation | ||
+ | * Toxo vs. lymphoma | ||
+ | * lymphoma will have uptake | ||
+ | * Others | ||
+ | * Contusion | ||
+ | * Malignancy | ||
+ | * uptake < gray matter -> low-grade tumor (WHO grade 1-2) | ||
+ | * uptake | ||
+ | |||
+ | ===== Brain flow ===== | ||
+ | * can be done w/ any agent | ||
+ | * good bolus, must see B carotids | ||
+ | * hot nose - secondary sign = nonspecific | ||
+ | * trident sign - visualization of MCA(lateral) ACA(middle) | ||
+ | * can't suggest brain death if patient is hypothermic | ||
+ | ===== Cisternogram ===== | ||
+ | * LP injection | ||
+ | * 30m intrathecal | ||
+ | * 4h basal cisterns | ||
+ | * 24h convexities | ||
+ | * 48h clearance | ||
+ | * ind- comm HCP, CSF leak | ||
+ | |||
+ | ====== Pulmonary ====== | ||
+ | ===== General ===== | ||
+ | * ALWAYS ask for CXR | ||
+ | |||
+ | ==== PIOPED ==== | ||
+ | === High Probability === | ||
+ | * 80-100% likelihood for PE | ||
+ | - Greater than or equal to 2 large mismatched segmental perfusion defects or the arithmetic equivalent in moderate or large and moderate defects. A high probability lung scan confirms a very high likelihood for pulmonary embolism and justifies treatment with anticoagulation (unless contraindicated) | ||
+ | * It has been suggested that 2.5 mismatched large segmental defects (or the arithmetic equivalent) is a better threshold for calling a scan high probability, | ||
+ | === Intermediate Probability === | ||
+ | * 20-80% likelihood for PE | ||
+ | - One moderate to 2 large mismatched perfusion defects or the arithmetic equivalent in moderate or large and moderate defects | ||
+ | - Single matched ventilation-perfusion defect with a clear chest radiograph | ||
+ | * Single ventilation-perfusion matches are borderline for "low probability" | ||
+ | - Difficult to categorize as low or high, or not described as low or high. | ||
+ | === Low Probability === | ||
+ | * 0-19% likelihood for PE | ||
+ | - Perfusion defects matched by ventilation abnormality provided that there are: (a) clear chest radiograph and (b) some areas of normal perfusion in the lungs | ||
+ | * Extensive matched V/Q abnormalities are appropriate for low probability, | ||
+ | - Any perfusion defect with a substantially larger chest radiographic abnormality | ||
+ | - Any number of small perfusion defects with a normal chest radiograph | ||
+ | - Nonsegmental perfusion defects (e.g., cardiomegaly, | ||
+ | - Multiple matched V/Q abnormalities, | ||
+ | * The prevalence of PE in patients with extensive matched V/Q defects and no CXR abnormality was 14% (low probability) | ||
+ | === Normal === | ||
+ | - No perfusion defects or perfusion exactly outlines the shape of the lungs seen on the chest radiograph (note that hila and aortic impressions may be seen and the chest radiograph and/or ventilation study may be abnormal) | ||
+ | ==== Defect Descriptors, | ||
+ | * " | ||
+ | * " | ||
+ | * " | ||
+ | |||
+ | ===== Xe 133 ===== | ||
+ | * inhaled | ||
+ | * single breath, equilibrium, | ||
+ | ===== Tc DTPA ===== | ||
+ | * must do before MAA | ||
+ | ===== Tc MAA ===== | ||
+ | * 70-500K particles | ||
+ | * free tec - thyroid, kidneys | ||
+ | * R -> L shunt - brain, kidneys | ||
+ | * abnl abd uptake - shunt, free tec, or small particle size | ||
+ | |||
+ | ====== Renal ====== | ||
+ | ===== Tc DMSA ===== | ||
+ | * cortical agent | ||
+ | * pyelo, cyst, abscess, scar, berthin | ||
+ | * indications: | ||
+ | * first UTI | ||
+ | * mass vs. column of berthin | ||
+ | |||
+ | |||
+ | |||
+ | |||
+ | ===== Mag 3 ===== | ||
+ | * 10 mCi | ||
+ | * Lasix 10mg | ||
+ | * no excretion first 2 min | ||
+ | * tubular agent | ||
+ | * on a transplant study, look for -> thrombosis, leak, obstruct | ||
+ | * normal values: | ||
+ | * time to peak = 2-4 min | ||
+ | * half life <10 min | ||
+ | * 10-20 min = indeterminate | ||
+ | * >20 min = abnormal | ||
+ | * split renal fxn | ||
+ | * normal = 43-50% | ||
+ | * borderline = 40-43% | ||
+ | * minimum clinically significant interval change = 6% | ||
+ | |||
+ | ===== Captopril renography ===== | ||
+ | * renovascular HTN | ||
+ | * threshold is 20% asymmetric decline in function | ||
+ | |||
+ | ====== Cardiac ====== | ||
+ | |||
+ | |||
+ | |||
+ | ===== General ===== | ||
+ | |||
+ | * Coronary artery dominance | ||
+ | * PDA arises from: | ||
+ | * RCA = right dominant (most common) | ||
+ | * LCX = left dominant | ||
+ | * DDx right ventricular uptake is RVH or R heart strain | ||
+ | |||
+ | ==== Interpretation ==== | ||
+ | * High-risk | ||
+ | * Large perfusion defect on stress imaging | ||
+ | * Multiple coronary artery territories | ||
+ | * Large reversibility | ||
+ | * Increased lung upake | ||
+ | * Transient LV dilitation | ||
+ | * Low-risk | ||
+ | * Normal stress images | ||
+ | * Small stress defect | ||
+ | * Small reversibility | ||
+ | * Look for extracardiac activity | ||
+ | * Lung activity = sign of extensive CAD and poor prognosis | ||
+ | * Lung nodule | ||
+ | * Parathyroid adenoma | ||
+ | ==== Transient Ischemic Dilitation ==== | ||
+ | * TID > 1.22 is abnormal with exercise stress | ||
+ | * TID > 1.36 is abnormal with physiologic stress | ||
+ | |||
+ | ===== Exercise Stress ===== | ||
+ | * Bruce protocol (3 min stages, increasing speed and incline) | ||
+ | * 12 lead EKG | ||
+ | * insert IV | ||
+ | * stop for drop in BP, v tach, chest pain, ST depression, or patient unable to continue (last 3 are relative) | ||
+ | * don't stress patients with aortic stenosis, L main disease | ||
+ | * Satisfactory Effort | ||
+ | * 85% max predicted hr | ||
+ | * double product >25,000 (product of HR x SBP) | ||
+ | |||
+ | ===== Adenosine ===== | ||
+ | * 140 ug/kg/min | ||
+ | * 6m infusion, inject @ 3m | ||
+ | * contraindications - bronchospasm (COPD/ | ||
+ | * aminophylline | ||
+ | * Adenosine induced heart block | ||
+ | * d/c adenosine (half life in range of seconds, so heart block will break) | ||
+ | * restart with lower dose (heart block is dose dependent) and complete the study | ||
+ | ===== Dobutamine ===== | ||
+ | * 6m min | ||
+ | * contraindications - MI, HTN | ||
+ | |||
+ | ===== MuGA ===== | ||
+ | * most accurate LVEF | ||
+ | * nl > 50% | ||
+ | * <45% EF is bad, decreasing EF to this level means stop therapy | ||
+ | * EF = (EDV - ESV) / (EDV - background) | ||
+ | * place background in lung next to LV or possibly in stomach | ||
+ | * background over spleen NOT okay - overestimates EF | ||
+ | * 24 frames per r-r interval | ||
+ | |||
+ | ====== Miscellaneous ====== | ||
+ | |||
+ | ===== Tc RBC ===== | ||
+ | ==== Labeling Technique ==== | ||
+ | * In vivo | ||
+ | * stannous pyrophosphate is administered intravenously, | ||
+ | * Modified in vivo | ||
+ | * stannous pyrophosphate is administered intravenously | ||
+ | * 15-30 minutes later, 3-5mL of blood is withdrawn into a shielded syringe containing < | ||
+ | * blood is incubated for 10 min (agitating periodically) and then infused | ||
+ | * In vitro | ||
+ | * blood is withdrawn and placed in a closed vial containing stannous chloride and sodium hypochlorite (oxidizes excess extracellular stannous ion and prevents extracellular reduction of < | ||
+ | * < | ||
+ | * hemangioma, blood vol, MUGA, GI bleeding | ||
+ | * criteria for GI bleed - not present @ beginning, increased act, movement | ||
+ | |||
+ | ===== Free pertecnetate ===== | ||
+ | * activity in stomach, kidney, thyroid, salivary glands, choroid, bladder | ||
+ | * Meckel' | ||
+ | * increased activity over time paralleling activity in stomach | ||
+ | |||
+ | ====== One-liners ====== | ||
+ | * Honda sign = sacral insufficiency fx | ||
+ | * Kasai procedure done w/i 3 months age | ||
+ | * Gastrinomas usually located in small bowel or pancreas | ||
+ | * Think EG for cystic bone lesions with a normal bone scan (they can be hot, too) or myeloma/ | ||
+ | * Increased uptake in one hand, think radial artery injection | ||
+ | * When shown myositis ossificans, also think of a parosteal osteosarcoma | ||
+ | * Interstitial lung dz can have hot lung bases on MDP | ||
+ | |||
+ | ====== Differentials ====== | ||
+ | ===== Hot mets on bone scan ===== | ||
+ | * Mucinous adenoCA | ||
+ | * Other adenoCA | ||
+ | * MDP goes to areas of cell death | ||
+ | |||
+ | ===== Cold defect on bone scan (HM RANT) ===== | ||
+ | * Hemangioma/ | ||
+ | * Myeloma/ | ||
+ | * RCC | ||
+ | * Anaplastic (aggressive) tumors | ||
+ | * Neuroblastoma | ||
+ | * Thyroid CA | ||
+ | * AVN, XRT, cold osteo | ||
+ | |||
+ | ===== Superscan ===== | ||
+ | * **Metabolic** | ||
+ | * Renal osteodystrophy | ||
+ | * Osteomalacia | ||
+ | * randomly distributed focal sites of intense activity (Looser zones/ | ||
+ | * Hyperparathyroidism | ||
+ | * focal intense uptake corresponds to site of brown tumors | ||
+ | * Hyperthyroidism | ||
+ | * rate of bone resorption more increased than rate of formation | ||
+ | * Widespread bone lesions | ||
+ | * **Diffuse skeletal metastases** | ||
+ | * prostate, breast, multiple myeloma, lymphoma, lung, bladder, colon, stomach | ||
+ | * Myelofibrosis/ | ||
+ | * Aplastic anemia, leukemia | ||
+ | * Waldenstrom macroglobulinemia | ||
+ | * Systemic mastocytosis | ||
+ | * **Widespread Paget disease** | ||
+ | |||
+ | ===== One Lung Absent Perfusion ===== | ||
+ | * hilar mass | ||
+ | * pulmonary artery agenesis | ||
+ | * unilateral PE | ||
+ | * Swyer-James (will have poor ventilation, | ||
+ | |||
+ | ===== Increased MDP Soft Tissue Uptake ===== | ||
+ | * lymphedema | ||
+ | * venous obstruction | ||
+ | * RSD | ||
+ | * infection (cellulitis) | ||
+ | |||
+ | |||
+ | ===== Focal Increased MDP Three Phase Activity ===== | ||
+ | * osteomyelitis | ||
+ | * fracture | ||
+ | * AVN | ||
+ | * surgery (osteotomy) | ||
+ | * primary or secondary neoplasm | ||
+ | * osteoid osteoma | ||
+ | * RSD (Uptake involves entire extremity. 50% of patients have increased blood flow and blood pool uptake, while 95% have increased uptake on delayed images.) | ||
+ | * charcot joint | ||
+ | * severe osteoarthritis | ||
+ | |||
+ | ===== Increased Cortical MDP Uptake ===== | ||
+ | * hypertrophic osteoarthropathy | ||
+ | * renal osteodystrophy | ||
+ | * vitamin A intoxication | ||
+ | * fluorosis | ||
+ | * thyroid acropachy | ||
+ | * manifestation of grave' | ||
+ | * melorheostosis/ | ||
+ | * pachydermoperiostosis | ||
+ | * idiopathic, familial hypertrophic osteoarthropathy | ||
+ | |||
+ | ===== Monoarticular Arthritis ===== | ||
+ | * Gout, PVNS, TB, septic arthritis | ||
+ | ===== Young Child w/ Hot Lesion on bone scan ===== | ||
+ | * neuroblastoma (95% are hot since 95% calcify) | ||
+ | |||
+ | ====== Diseases ====== | ||
+ | ===== Dementia with Lewy Bodies (DLB) ===== | ||
+ | * second most common senile dementia (after Alzheimer' | ||
+ | * Lewy bodies = eosinophilic structures w/i neurons | ||
+ | * overlap with Alzheimer' | ||
+ | * FDG-PET shows diffuse glucose hypometabolism, | ||
+ | |||
+ | |||
+ | |||
+ | ====== Artifacts ====== | ||
+ | * off-peak flood - every other PMT lights up | ||
+ | |||
+ | ====== Quality Control ====== | ||
+ | |||
+ | ===== Gamma Camera QC ===== | ||
+ | ==== Peak ==== | ||
+ | * daily and with each new RP | ||
+ | ==== Flood ==== | ||
+ | * daily, <5% uniformity | ||
+ | * intrinsic | ||
+ | * extrinsic | ||
+ | ==== Linearity and resolution ==== | ||
+ | * weekly with bar phantom | ||
+ | ==== Field Uniformity and Center of Rotation ==== | ||
+ | * monthly | ||
+ | |||
+ | ===== Spect QC ===== | ||
+ | ==== Flood ==== | ||
+ | * uniformity < 1% | ||
+ | ==== COR and detector malalignment ==== | ||
+ | * ring and comet tail artifacts on axial recons | ||
+ | ==== Motion ==== | ||
+ | * sinogram | ||
+ | * summed projection | ||
+ | * cine | ||
+ | ==== Attenuation ==== | ||
+ | * evaluation cine images for evidence of attenuation | ||
+ | * attenuation correction | ||
+ | |||
+ | ===== PET QC ===== | ||
+ | ==== Check scan (blank) ==== | ||
+ | * daily | ||
+ | ==== Bucket setup ==== | ||
+ | * when system is drifting | ||
+ | ==== 2D and 3D normalization ==== | ||
+ | * weekly to monthly or after bucket setup | ||
+ | ==== Phantom calibration ==== | ||
+ | * on new < | ||
+ | |||
+ | ===== Dose Calibrator QC ===== | ||
+ | * All doses must be measured prior to administration and be within 10% of prescribed dose | ||
+ | * Isotopes used for dose calibrator QC include < | ||
+ | ==== Constancy ==== | ||
+ | * < | ||
+ | * reproducibility in measuring a constant source over a long period of time | ||
+ | ==== Channel Check ==== | ||
+ | * < | ||
+ | ==== Linearity ==== | ||
+ | * quarterly | ||
+ | * ablility of calibrator to indicate the correct activity over the range of use of that calibrator | ||
+ | ==== Accuracy ==== | ||
+ | * annually | ||
+ | * for a given calibrated reference source, the indicated millicurie value is equal to the millicurie value determined by the National Bureau of Standards (NBS) or by the supplier who has compared that source to a source that was calibrated by the NBS | ||
+ | * at least two sources with different principal photon energies (such as Co-57, Co-60, or Cs-137) should be used; one must have a principal photon energy between 100 keV and 500 keV | ||
+ | ==== Geometry ==== | ||
+ | * checked at installation | ||
+ | * indicated activity does not change with volume or configuration | ||
+ | |||
+ | ===== Radiopharmaceutical QC ===== | ||
+ | ==== Sterility ==== | ||
+ | * pyrogens detected with limulus test | ||
+ | |||
+ | ==== Chemical Purity ==== | ||
+ | * < 10 µg/ml Al3+ in 99mTc eluate | ||
+ | |||
+ | ==== Radionuclide Purity ==== | ||
+ | * 0.15µCi of 99Mo / 1.0 mCi of 99mTc | ||
+ | |||
+ | ==== Radiochemical Purity ==== | ||
+ | * free 99mTcO4-, reduced 99mTcO2, tin colloids | ||
+ | * reduced and tin colloids localize to RES | ||
+ | |||
+ | ====== NRC Guidelines ====== | ||
+ | * authorized user - may order, receive and inject isotopes | ||
+ | * protocol | ||
+ | * identify patient -> 2 forms of ID (name and birthdate) | ||
+ | * confirm order | ||
+ | * have pt state ID and procedure they' | ||
+ | * informed consent | ||
+ | * written directive analagous to prescription for therapy | ||
+ | |||
+ | ====== Radiation Safety ====== | ||
+ | |||
+ | ===== Decay Mechanisms ===== | ||
+ | * isomeric transition (99mTc -> 99Tc + ) | ||
+ | * 99mTc | ||
+ | * positron (+) decay | ||
+ | * 18F, 15O, 13N, 11C, 68Ga | ||
+ | * generally high radiation dose | ||
+ | * negatron (-) decay | ||
+ | * 131I and 133Xe diagnostic, 32P, 90Sr, 90Y therapeutic, | ||
+ | * generally highest radiation dose | ||
+ | * electron capture | ||
+ | * 67Ga, 111In, 123I, 201Tl | ||
+ | |||
+ | ===== Common radionuclides ===== | ||
+ | |||
+ | ^ ^t½ ^keV ^ | ||
+ | |**< | ||
+ | | TcO4-, Mibi, RBCs, SC,| | | | ||
+ | | Mag-3, DTPA, DMSA, ECD| | | | ||
+ | | | | | | ||
+ | |**< | ||
+ | | Tl Chloride| | | | ||
+ | | | | | | ||
+ | |**< | ||
+ | | WBC, octreoscan, DTPA| | | | ||
+ | | | | | | ||
+ | |**< | ||
+ | | Ga citrate| | | | ||
+ | | | | | | ||
+ | |**< | ||
+ | | iodide, MIBG, NP59| | | | ||
+ | | | | | | ||
+ | |**< | ||
+ | | iodide, MIBG, NP59| | | | ||
+ | | | | | | ||
+ | |**< | ||
+ | | Xe gas| | | | ||
+ | | | | | | ||
+ | |**< | ||
+ | | FDG| | | | ||
+ | |||
+ | ===== Decay properties ===== | ||
+ | ==== t½ ==== | ||
+ | * 7 half lives < 1 % of original activity | ||
+ | * 10 half lives < 0.1 % | ||
+ | |||
+ | ==== inverse square law ==== | ||
+ | * dose 1 / d< | ||
+ | |||
+ | ==== HVL and TVL (shielding) ==== | ||
+ | ===== Gamma Camera ===== | ||
+ | ==== Gamma camera ==== | ||
+ | collimator, crystal, PMT, preamplifier, | ||
+ | |||
+ | ==== Collimators ==== | ||
+ | * resolution increases with | ||
+ | * increased collimator thickness | ||
+ | * decreased collimator hole diameter | ||
+ | * decreased patient to collimator distance | ||
+ | * parallel hole | ||
+ | * low, medium, or high energy | ||
+ | * general purpose or high resolution | ||
+ | * pinhole | ||
+ | * small parts, magnification, | ||
+ | * converging hole -> small FOV, magnification, | ||
+ | * diverging hole -> large FOV, minification, | ||
+ | * resolution inversely proportional to sensitivity | ||
+ | |||
+ | ====== 99Mo - 99mTc Generator ====== | ||
+ | * Reactor produced | ||
+ | * < | ||
+ | |||
+ | ===== 99Mo Breakthrough Test ===== | ||
+ | * NRC limit = 1.00 mCi < | ||
+ | * USP limit = 0.15 mCi < | ||
+ | ===== Aluminum Ion Breakthrough ===== | ||
+ | * Al< | ||
+ | * NRC limit = 20mg per mL of eluate (thermal generator) | ||
+ | * = 10mg per mL of eluate (fission generator) | ||
+ | * measured by colorimetry on filter paper | ||
+ | |||
+ | ====== Radiation Interaction with Matter ====== | ||
+ | ===== ===== | ||
+ | ==== photoelectric effect ==== | ||
+ | * complete absorption of with expulsion of e- with charactersitic X-rays | ||
+ | ==== internal conversion ==== | ||
+ | * completely absorbed by originating atoms e- shell with characteristic X-ray production | ||
+ | ==== Compton scatter ==== | ||
+ | * deflection of with loss of energy and nuclear excitation with characteristic X-rays production | ||
+ | ===== + ===== | ||
+ | ==== annihilation ==== | ||
+ | * + + - -> two 511keV rays at 180 degrees | ||
+ | ===== - and - ===== | ||
+ | ==== ionization ==== | ||
+ | * characteristic X-rays | ||
+ | |||
+ | ====== Exposure, Dose, Dose Equivalent ====== | ||
+ | * Bq = 1 dps | ||
+ | * 1 mCi = 37 MBq | ||
+ | |||
+ | ^ ^ SU ^ IU ^ | ||
+ | |X = Q/m|R|C/kg| | ||
+ | |D = E/m|100 rad|Gy| | ||
+ | |DE = D x Q|100 rem|Sv| | ||
+ | |||
+ | ====== Occupational Dose Limits ====== | ||
+ | |||
+ | |Background|0.3 rem / y| | ||
+ | | | | | ||
+ | |Whole body|5 rem / y| | ||
+ | |Lens|15 rem / y| | ||
+ | |Extremities / skin / organ|50 rem / y| | ||
+ | |Cumulative dose|1 rem x age| | ||
+ | | | | | ||
+ | |Fetus|0.5 rem / 9 m\\ 0.05 rem / m| | ||
+ | | | | | ||
+ | |General population|0.1 rem / y| | ||
+ | |||
+ | ====== Women, Pregnancy, and Lactation ====== | ||
+ | In women of childbearing age: | ||
+ | * check -HCG | ||
+ | * elective NM exams within 10 d of start of menses | ||
+ | * MD approval required (consent) | ||
+ | |||
+ | * fetal dose for rad workers 0.5 rem / 9 mo | ||
+ | * negligible dose < | ||
+ | |||
+ | For lactating females, stop breastfeeding: | ||
+ | * 99mTc label -> 24 hr | ||
+ | * 67Ga, 201Tl -> 2+ wks | ||
+ | * 131I -> stop breastfeeding | ||
+ | |||
+ | ====== Radiation safety general concepts ====== | ||
+ | ===== ALARA ===== | ||
+ | * as low as reasonably achievable | ||
+ | * non-threshold, | ||
+ | * distance, time, shielding | ||
+ | ===== Stochastic ===== | ||
+ | * dose proportional to risk of effect | ||
+ | * cancer / gene mutations | ||
+ | |||
+ | ===== Non-stochastic ===== | ||
+ | * threshold required before effect | ||
+ | * acute radiation syndrome, cataracts, sterility | ||
+ | |||
+ | ====== Receipt of Radioactive Materials ====== | ||
+ | * **Survey package within 3 hr of arrival** | ||
+ | * Geiger counter | ||
+ | * 3 levels, highest allowed = 100 mrem/hr @ surface, 3 mrem/hr @ 1 m | ||
+ | * confirm with wipe test | ||
+ | * needs to be less than 2200 DPM / 100 cm2 | ||
+ | * If elevated, notify NRC / state licensing agency and the package carrier, decontaminate or isolate package as necessary | ||
+ | |||
+ | ====== Radiation surveys ====== | ||
+ | ===== Daily Monitoring ===== | ||
+ | * hot lab, imaging rooms, radioassay lab, thyroid room | ||
+ | |||
+ | ====== Spills ====== | ||
+ | * If t ½ < 65 d, can use DIS (decay in storage), await background levels | ||
+ | * 10 half lives gives <0.1% of original radioactivity | ||
+ | |||
+ | ===== Minor spills ===== | ||
+ | * <1 mCi < | ||
+ | * secure area, survey people and clothes, contain spill | ||
+ | * clean up area and place soiled material in plastic bags | ||
+ | * incident report by RSO after cleaning | ||
+ | * resurvey area | ||
+ | * liquid iodide is volatile and may require special clean-up | ||
+ | * consider Lugols for exposed staff | ||
+ | |||
+ | ===== Major spills ===== | ||
+ | * warn workers, isolate area | ||
+ | * summon RSO who directs decontamination | ||
+ | * immediate assessment of type and extent of spill, warning signs | ||
+ | * initiation of medical care as indicated | ||
+ | * decontaminate workers | ||
+ | * clean area, waste placed in heavy plastic bag in shielded container | ||
+ | |||
+ | ====== Misadministration of Radiopharmaceuticals ====== | ||
+ | {{diagnosticmisadmin.jpg}}\\ | ||
+ | {{therapeuticmisadmin.jpg}} | ||
+ | |||
+ | ===== Medical event = recordable event ===== | ||
+ | ==== Diagnostic Misadministration ==== | ||
+ | * RP without written directive when required | ||
+ | * RP with written directive where administered RP dose is not recorded | ||
+ | * < | ||
+ | * dose > 110% prescribed, **and** | ||
+ | * dose exceeds prescribed by 15 µCi | ||
+ | |||
+ | ===== Reportable Events ===== | ||
+ | * Incident report filed by RSO and retained for 3 years. | ||
+ | * NRC / State licensing agency, referring MD, and patient (guardian) notified within 24 hours by phone, letter to NRC within 15 days. | ||
+ | * Incident report by RSO, address in RSC meeting, retain record for 20 yrs | ||
+ | |||
+ | ==== Diagnostic Misadministration ==== | ||
+ | * Radioiodine > 30 µCi | ||
+ | * wrong patient or wrong RP, **or** | ||
+ | * dose > 120% prescribed dose and difference exceeds 30 µCi | ||
+ | * Radioiodine doses < 30 µCi and all other radiopharmaceuticals | ||
+ | * wrong patient, wrong RP, wrong route, or dose exceeds 150% of that prescribed, **and** | ||
+ | * dose > 50 rem to organ, or > 5 rem to whole body | ||
+ | |||
+ | ==== Therapeutic Misadministration ==== | ||
+ | * Wrong patient, wrong RP, or wrong route, or | ||
+ | * dose > 120% of prescribed dose | ||
+ | ====== I-131 Therapy ====== | ||
+ | |||
+ | ===== Before Therapy ===== | ||
+ | * No IV contrast for at least 6? wks | ||
+ | * D/C synthroid 6 wks prior to therapy and start cytomel | ||
+ | * D/C cytomel 2 wks prior to therapy | ||
+ | * D/C PTU and methimazole 3 days before therapy | ||
+ | * Low iodine diet 1 wk prior to therapy | ||
+ | * 1-2 days prior to therapy, obtain labs | ||
+ | |||
+ | ===== Precautions ===== | ||
+ | - Always wash your hands with soap and water after you use the bathroom. Dry your hands thoroughly with a towel that only you are using | ||
+ | - Separate all towels, washcloths, and bed linens. Wash all of these items separate from the family wash | ||
+ | - In order to dilute the amount of radiation in urine and feces, always flush the toilet at least two or three times after using the bathroom | ||
+ | - Wash the bathroom sink, shower, bathtub and bidet after each use | ||
+ | - Separate your plates, silverware and drinking cups. Better yet, use paper plates and plastic cutlery, so you won't have to wash your dishes separately from the rest of the family | ||
+ | - If you are cooking for the family, remember not to taste any of the food with a spoon that will be used for food preparation. Once it touches the saliva in your mouth it is considered to be contaminated and must be washed separately | ||
+ | - Sleep in a separate bed from your partner. Avoid open mouth kissing and all sexual contact | ||
+ | - Radiation exposure is directly related to the amount of time you spend with another person as well as how intimate and close your contact is with them. Avoid prolonged intimate physical contact with babies, children and pregnant women. You may perform all essential duties such as changing diapers, if no one else is available to help you. Wash your hands before and after these tasks | ||
+ | - In order to flush out the radiation faster, keep yourself well hydrated (preferably with water) so that the radioactive iodine will be passed out of your body through your urine. | ||
+ | |||
+ | * These precautions should be followed for three days after the I131 test | ||
+ | |||
+ | ====== Clearance for discharge after therapeutic administration ====== | ||
+ | Contacts must receive < 500 mrem total body dose | ||
+ | * dose estimated by t ½ , expected duration of contact, and distance of contact | ||
+ | Transportation | ||
+ | * home from clinic / hospital | ||
+ | * highest dose rate | ||
+ | Close contacts | ||
+ | * shared bed | ||
+ | * longest exposure time with high dose rate | ||
+ | Casual contacts | ||
+ | * workplace, shared living space |
nukes.txt · Last modified: 2019/04/22 08:41 by nfasano